Table 1.

C1-INH treatment for ischemic stroke

Animals	Stroke models	Time of administration	Routes of injection	Time point of observations	Outcomes	Mechanisms	Refs
C57BL/6 mice	1 h MCAO	0.5 h before or 6 h after MCAO	Intravenous injection with IVIg or alone	72 h after MCAO	Reduced brain infarction size, neurological deficit and mortality	Reduced deposition of C3b and downregulated excessive TLR2 and p-JNK1 expression in the brain	[400]
C57BL/6 mice & CD rats	1 h MCAO (mice) & 1.5 h MCAO (rats)	1 h or 6 h after MCAO	Intravenous injection	24 h and 7 days after MCAO	Reduced infarct volumes and improved clinical scores	Reduced blood-brain barrier damage, edema formation, and inflammation	[366]
Sprague-Dawley rats	pMCAO or thromboembolic stroke	2 h or 4 h after MCAO	Intravenous injection with tPA or alone	24 h after MCAO	Reduced intracranial hemorrhage and neurological scores	Not studied	[428]
C57Bl/6 mice	0.5 h MCAO or pMCAO	0 h, 3 h, 6 h, or 18 h after MCAO	Intravenous injection	48 h and 7 days after MCAO	Reduced brain infarct volumes and CD45+ cell infiltration in the brain	Not studied	[367]
CD1 mice	2 h MCAO	Immediately after ischemia	Intravenous injection	48 h after MCAO	Attenuated general and focal neurological deficits	Reduced TNF-a, IL-18, ICAM-1 and P-selectin mRNA expression and microglia activation; Enhanced IL-6 and IL-10 mRNA expression	[369]
C57BL/6	0.5 h MCAO	15 min after ischemia	Intravenous injection	4 days after MCAO	Reduced general and focal neurological deficit scores and neuronal degeneration	Reduced CD45+ cell infiltration in the brain	[33]
CD1 mice	2 h MCAO	15 min after MCAO	Intravenous injection	48 h after MCAO	Reduced infarct volume and neuronal death	Did not affect astrocyte response	[364]
Wistar rats	1 h MCAO	Just before MCAO	Intravenous injection	48 h after MCAO	Reduced infarct volume and leukocyte infiltration in the brain	Not studied	[429]